HMGB-1, TLR4, IL-1R1, TNF-α, and IL-1β: novel epilepsy markers?

Aim. The purpose of this studywas to compare HMGB-1, TLR4, IL-1 beta, IL-1R1, and TNF-alpha levels in patients with mild and severe epilepsy with those in a healthy control group. Methods. Children aged 4-17 years, diagnosed with epilepsy for at least three years and with no progressive neurological disease, metabolic disease or infection, were selected for the study. The severe epilepsy group consisted of 28 children with at least one episode aweek despite receiving three or more antiepileptic drugs. The mild epilepsy group consisted of 29 children with no seizures in the previous year, receiving only one antiepileptic drug, while 27 healthy childrenwere selected as the control group. HMGB-1, TLR4, IL-1R1, TNF-alpha and IL-1 beta levelswere investigated in these three groups. The MRI findings and clinical characteristics of the patients in the epilepsy group were also compared with these markers. Results. HMGB-1, TLR4, TNF-alpha, and IL-1 beta levels in the severe epilepsy group were higher than in the control group and the mild epilepsy group (p<0.05), and were higher in the mild epilepsy group than in the control group (p<0.05). IL-1R1 was also higher in the severe epilepsy group than in the control group (p<0.05). Conclusion. In this first report to identity a possible correlation between HMGB-1, TLR4, IL-1 beta, IL-1R1, and TNF-alpha levels and severity of epilepsy, our data demonstrates that the serum level of these cytokines is higher in cases of drug-refractory epilepsy.